Over the past decade, the rising cost of insulin epitomized the broader systemic issue of higher healthcare out-of-pocket ...
Citi Pharma Limited (CPHL), a Pakistani pharmaceutical company, has decided to venture into the real estate sector with the ...
Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...
6d
GlobalData on MSNTripartite MoU signed for mRNA production platform in EgyptFrench company DNA Script will contribute its enzymatic DNA synthesis technologies, while Quantoom of Belgium will bring its ...
as well as establishing a $35 cap on out-of-pocket costs for Lantus. A spokesperson for the company stated, “Sanofi believes that no one should struggle to pay for their insulin, regardless of ...
28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% insulin aspart protamine suspension ...
Last year, non-profit drugmaker Civica Rx pledged to launch biosimilars of three big-selling insulin products in the US – Sanofi's Lantus, Novo Nordisk's Novolog, and Lilly's Humalog – by 2024.
The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...
Its revenue from operations during the reported quarter stood at Rs 721 crore. This marks a rise of nearly 3 percent from the Rs 701 crore revenue from operations reported in Q3 of FY24.
Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio ...
Global Diabetes Drug Market growth is driven by the rising incidence of diabetes and increasing adoption of innovative treatment solutions.Austin, United States, Feb. 10, 2025 (GLOBE NEWSWIRE) -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results